Equities research analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to announce ($0.13) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from ($0.20) to ($0.02). Conatus Pharmaceuticals also reported earnings of ($0.13) per share in the same quarter last year. The company is expected to report its next quarterly earnings report on Wednesday, November 7th.

Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Conatus Pharmaceuticals.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.05. Conatus Pharmaceuticals had a negative return on equity of 69.68% and a negative net margin of 48.46%. The firm had revenue of $8.77 million for the quarter, compared to analysts’ expectations of $9.06 million.

A number of research firms have recently weighed in on CNAT. Oppenheimer set a $14.00 target price on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. Finally, ValuEngine upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Conatus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $12.50.

Shares of Conatus Pharmaceuticals stock traded up $0.79 during trading on Monday, reaching $5.20. 1,516,571 shares of the stock were exchanged, compared to its average volume of 184,470. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.68. The firm has a market cap of $124.50 million, a P/E ratio of -8.52 and a beta of 1.23. Conatus Pharmaceuticals has a 1 year low of $3.22 and a 1 year high of $7.95.

Several institutional investors have recently bought and sold shares of CNAT. The Manufacturers Life Insurance Company boosted its holdings in shares of Conatus Pharmaceuticals by 253.0% during the first quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 16,476 shares during the period. Jane Street Group LLC purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter worth about $142,000. MYDA Advisors LLC purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter worth about $154,000. Wells Fargo & Company MN boosted its holdings in shares of Conatus Pharmaceuticals by 77.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,036 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 14,848 shares during the period. Finally, LMR Partners LLP purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter worth about $311,000. Institutional investors own 34.93% of the company’s stock.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Featured Story: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.